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ABSTRACT − Combining cell- and gene-based therapy is a promising therapeutic strategy in regenerative medicine. The
aim of this study was to develop genetically modified mesenchymal stem cell (MSC) aggregates using a poly(ethylene gly-
col) (PEG) hydrogel micro-well array technique. Stable PEG hydrogel micro-well arrays with diameters of 200 to 500 µm
were fabricated and used to generate genetically engineered MSC aggregates. Rat bone marrow-derived MSCs were trans-
fected with a green fluorescent protein (GFP) plasmid as a reporter gene, and aggregated by culturing in the PEG hydrogel
micro-well arrays. The resultant cell aggregates had a mean diameter of less than 200 µm, and maintained the mesenchymal
phenotype even after genetic modification and cell aggregation. Transplantation of MSC aggregates that are genetically
modified to express therapeutic or cell-survival genes may be a potential therapeutic approach for regenerative medicine.
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Transplantation of progenitor/stem cells has been studied
over the last decade as a promising treatment for the regen-
eration of damaged tissues (Humes et al., 2003). Bone mar-
row-derived mesenchymal stem cells (MSCs), in particular,
have received recent attention in the cell therapy field, because
of their numerous beneficial properties such as self-renewal
ability, multipotential nature, regenerative and immunomod-
ulatory potential, and genetic stability (Tae et al., 2006).
Despite increasing experimental and clinical interest in using
MSCs in regenerative medicine, clinical MSC-based thera-
peutic approaches have not been well established because poor
cell viability and low engraftment limit the therapeutic efficacy
of MSC transplantation (Pittenger et al., 2004). To overcome
the lack of long-term MSC engraftment and low-level engraft-
ment efficiency, the genetic modification to promote MSC via-
bility and therapeutic efficacy has been suggested as a
potentially effective approach to tissue repair and regeneration
(Cheng et al., 2008; Noiseux et al., 2006). For instance, genet-
ically modifying MSCs to produce growth factors, such as
VEGF and IGF-I, improved their retention and growth prop-
erties after cell transplantation into ischemic myocardium in
rats (Pons et al., 2008; Sadat et al., 2007).
In recent years, microfabricated cell clusters or aggregates
have been used in biomedical applications, such as cell ther-
apy, tissue engineering, developmental biology, and drug dis-
covery (Gallego-Perez et al., 2010). In particular, transplantation
of different types of assembled cell clusters including cell
aggregates and cellular sheets has been suggested for tissue
repair and regeneration. Transplantation of a group of cells
markedly improves cell survival rates and transplantation effi-
ciencies compared to injection of single cells (Kato et al.,
1993). In this study, genetically engineered MSC aggregates
prepared by a microfabrication technique were developed for a
combination cell- and gene- therapy approach. To generate
genetically modified MSC aggregates, micro-well arrays were
made using PEG hydrogels. Green fluorescent protein (GFP)
plasmid was used as a reporter gene to assess the possibility of
the fabrication of MSC aggregates expressing exogenous tar-
get genes without causing phenotypic changes. When used
with therapeutic target genes such as cell survival and angio-
genic factors, this technique to generate genetically engineered
MSC aggregates may provide a promising strategy for regen-
erative therapy applications.
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Materials and Methods
Materials
SU-8 photoresist was purchased from Microchem Corp.
(Newton, MA, USA). Poly(dimethylsiloxane) (PDMS) was
obtained from Dow Corning Corp. (Midland, MI, USA).
Poly(ethylene glycol)-diacrylate (PEG-diacrylate, 1,000 Da)
was supplied by PolySciences Inc. (UK). Irgacure 2959 was
obtained from Ciba Specialty Chemicals Corp. (Tarrytown,
NY, USA). 3-(Trimethoxysilyl)propylmethacrylate (TMSPMA),
linear poly(ethylenimine) (LPEI, mw = 25 kDa), and penicillin/
streptomycin solution were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Ficoll-Paque Plus was supplied by Amer-
sham Biosciences (Uppsala, Sweden). The peGFP-C1 vector
was obtained from BD Bioscience Clontech (Palo Alto, CA,
USA). Fetal bovine serum (FBS), Dulbecco’s modified Eagle’s
medium (DMEM), and Dulbecco's phosphate-buffered saline
(PBS) were supplied by Gibco BRL (Grand Island, NY, USA).
All other chemicals and reagents were used as received unless
otherwise noted. 
Fabrication of PEG hydrogel micro-well arrays
PEG hydrogel micro-well arrays were generated by pho-
tolithography and micro-molding techniques. Briefly, SU-8
photoresist was spin-coated on a silicon wafer and exposed to
UV light, resulting in micropatterns with 200 µm to 500 µm in
diameter. After the photolithography process, PDMS mixed
silicone elastomer with curing agent (10:1) was poured into a
SU-8 photoresist-patterned silicon wafer, and baked at 70oC
for 2 h. To generate PEG micro-well arrays, PEG-diacrylate
was mixed with 1% Irgacure 2959. PDMS stamps were gently
placed on PEG prepolymer solutions on a glass substrate and
exposed to UV light (EXFO Photonic Solutions Inc., Omn-
iCure, Canada, 50 mW/cm2) for 50 sec. To enhance the bond-
ing between PEG micro-well arrays and glass substrates, glass
substrates were treated with TMSPMA for 30 min and baked
at 70oC for 2 hours. After removing the PDMS stamps, PEG
micro-well arrays of 200 µm, 300 µm, and 500 µm in diameter
were generated on the glass substrates. Morphological obser-
vation of the PEG hydrogel micro-well arrays was carried out
with scanning electron microscopy (SEM, Philips 535 M,
Netherlands) and optical images were generated under light
microscopy (100 × magnification).
MSC preparation, culture, and characterization
MSCs were isolated from the bone marrow of four-week-old
male Sprague-Dawley rats (Samtako Bio Co., Osan, Korea).
The use of animals was in accordance with the International
Guide for the Care and Use of Laboratory Animals. Rat MSCs
were harvested and propagated as described previously (Song
et al., 2007; Chang et al., 2009). Briefly, the rat bone marrow-
derived cells were flushed out from femurs and tibias with cul-
ture medium (DMEM with 10% FBS). Mononuclear cells
were isolated by Ficoll-Paque density gradient centrifugation.
After 48 h incubation, non-adherent cells were discarded, and
adherent cells were expanded until confluent. MSCs were cul-
tured in DMEM supplemented with 10% FBS and 1% pen-
icillin-streptomycin up to 80% confluency for three or four
passages before use. 
In vitro transfection
For in vitro transfection, MSCs were plated at a density of
1.0 × 106 cells in a 100 mm tissue culture dish. After 48 h of
incubation, the culture medium was exchanged with fresh
serum-free medium. Cells were transfected with 6 µg of
peGFP prepared with LPEI at a N/P ratio (nitrogen of PEI/
phosphate of DNA) of 10:1. After 4 h for transfection, the
medium was replaced with fresh 10% serum medium. Trans-
fected cells were incubated at 37oC for 24 h and used for the
formation of MSC aggregates using the PEG hydrogel micro-
well arrays. GFP expression in MSC aggregates was visualized
by a confocal laser scanning microscope (Olympus Fluoview
FV300, Melville, NY) using an argon-krypton mixed gas laser
(Ex. 494 nm). The nuclei of MSCs were stained with 4',6-dia-
midino-2-phenylindole (DAPI, 1 µg/mL, Molecular Probes
Inc., Eugene, OR, USA) for 30 min one day before MSC
aggregates formation, according to the manufacturer’s sug-
gested protocol.
Preparation of MSC aggregates
PEG hydrogel micro-well arrays were washed three times
with PBS and exposed to UV for 30 min for sterilization. After
the fourth passage, rat MSCs grown in monolayer cultures
were trypsinized, resuspended in media, counted with a hema-
cytometer, and plated onto the PEG micro-wells at 1.0 × 106
cells/plate with 0.2 mL culture medium. Cells were allowed to
settle into the micro-wells for 4 h before the PEG micro-well
arrays were washed with a gentle flow of culture medium to
remove undocked cells. Seeded micro-wells were incubated at
37oC and 5% CO2 for 2 days. The diameters of the resultant
MSC aggregates were directly measured from optical images
taken for a total of 50 cell aggregates at three different regions
of the specimen. To assess the MSC phenotype, cultured single
MSCs and peGFP-modified MSC aggregates were labeled
against positive and negative cell-surface markers, CD90-flu-
orescein isothiocyanate (FITC) and CD34-phycoerythrin (PE)
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(BD Biosciences, San Diego, CA), and analyzed by flow
cytometry. In brief, harvested cells were incubated with anti-
bodies (0.5 mg/mL) for 15 min at room temperature and
washed twice with PBS. After staining with fluorescence-
labeled monoclonal antibodies, fluorescence intensity was
detected using fluorescence-activated cell sorting analysis
(Becton Dickinson, San Jose, CA).
Results and Discussion
To develop a novel cell- and gene-based therapy strategy for
efficient tissue regeneration, genetically engineered MSC
aggregates were prepared using a micro-well array technique.
The fabrication process for genetically modified MSC aggre-
gates is schematically described in Figure 1. Isolated MSCs
were transfected with LPEI (25 kDa) as a polymeric gene car-
rier and an eGFP plasmid as a reporter gene. The genetically
modified MSCs were loaded into the microfabricated wells to
generate small cell clusters. After two days of culture, the final
MSC aggregates were harvested from the micro-well plates. 
For the fabrication of the PEG hydrogel microstructures on
the glass substrates, a photolithographic method based on
PDMS stamps was used (Xue et al., 2010). As shown in Figure
2, microfabricated arrays of PEG hydrogel micro-wells with
different pore diameters of 200 µm, 300 µm, and 500 µm were
produced. To investigate the influence of micro-well array pore
size on the extent of cell cluster formation, unmodified MSC
aggregates were prepared using micro-wells of different sizes.
MSC aggregate sizes were determined by median diameters
measured from optical images selected at random. Although
the pore sizes of the micro-well arrays were not directly
reflected in the results of MSC aggregate formation, cell aggre-
gate size increased with increasing pore size in the PEG hydro-
gel micro-well arrays from 200 µm to 500 µm (Figure 3). The
cell mass of the aggregates, however, did not expanded indef-
initely with increasing micro-well pore size. The MSC aggre-
Figure 1. Schematic representation of the preparation of genetically engineered MSC aggregates using PEG hydrogel micro-well array
technology. The inset is a representative optical image of a PEG hydrogel micro-well array with a 200 µm diameter.
Figure 2. SEM images of PEG hydrogel micro-well arrays for different pore sizes: (A) 200 µm; (B) 300 µm; and (C) 500 µm diameters.
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gates generated by the micro-well array technique generally
reached a maximum of around 200 µm. Specifically, cell
aggregate sizes obtained from micro-wells had diameters of
100.2 ± 12.56 µm for 200 µm pores, 152.4 ± 14.27 µm for
300 µm pores, and 206.7 ± 27.92 µm for 500 µm pores. Since
low gauge needles cause a lot of tissue damage and scar for-
mation with repeated injections, needles with a gauge over 30
(an inner diameter of ca. 150 µm) are commonly used in ani-
mal experiments to avoid the tissue damage and pain asso-
ciated with cell therapy injections (Ratcliff et al., 2008).
Therefore, MSC aggregates with a size of less than 150 µm
could be efficiently used as injectable cell aggregates for ther-
apeutic applications in the field of tissue engineering and
regenerative medicine. 
After in vitro cell transfection with an interesting gene, MSC
aggregates were prepared with the micro-well-based fabrica-
tion method (Figure 4). Figures 4 A and B show the successful
formation of micro-scale spherical MSC aggregates using the
PEG hydrogel micro-well technique. As shown in Figures 4 C
and D, eGFP-modified MSC aggregates exhibited GFP
expression in their constituent cells, although the observed
gene expression level was low. Induction of in vitro gene
expression is highly dependent upon the selection of appro-
priate gene carriers, and dependent on cell-related factors such
as cell type and cell conditions. Since primary cells including
adult bone marrow-derived MSCs show very low in vitro
transfection efficiencies of generally no more than a few per-
cent using common transfection methodologies (Haleem-
Smith et al, 2005; Otani et al., 2009), the development of effi-
cient transfection reagents for MSCs is needed for successful
therapeutic approaches using genetically engineered MSC
aggregates. To exclude the possibility that the genetic mod-
ification and cell aggregation processes caused phenotypic
changes of the MSCs, phenotypic analysis of intact MSCs and
eGFP-modified MSC aggregates was conducted by flow
cytometry after staining for positive (CD90) and negative
(CD34) MSC membrane surface markers. As shown in Figure
5, no phenotypic changes were observed in MSCs after eGFP
modification and cell aggregate formation, possibly due to the
genetic stability of MSCs, which is one of their advantages
mentioned above (Pittenger et al., 2004; Mosca et al., 2000).
Thus, the transplantation of genetically engineered MSC
aggregates prepared through a micro-well array method could
be suggested as a potential therapeutic toll in regenerative
medicine strategies.
In conclusion, this work provides a platform technology for
Figure 3. Sizes of MSC aggregates produced by PEG hydrogel
micro-well arrays with different pore sizes. ns = not significant. 
Figure 4. (A,B) Phase contrast images of MSC aggregates and
(C,D) fluorescence images of eGFP-modified MSC aggregates
stained with DAPI (blue). Scale bar is 200 µm.
Figure 5. Phenotypic analysis of MSCs surface markers. MSCs and
eGFP-modified MSC aggregates were stained for different
selectable markers (positive: CD90, blue; negative: CD34, red). An
unstained MSC sample was used as a negative control (black). M
refers to the gated area (fluorescence intensity in arbitrary units:
101-104).
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the production of genetically engineered MSC aggregates, that
can be applied for combined cell and gene therapy. Using a
PEG hydrogel micro-well array technique, we successfully
generated genetically modified MSC aggregates without
changing phenotype. With efficient MSC transfection meth-
odologies and potential therapeutic target genes, this novel fab-
rication approach has potential for use in regenerative
technology.
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